Gilead’s Trodelvy Wins In TROPiCS-02, But Commercial Headwinds Remain

Gilead Sciences, Inc.’s latest results from the closely watched TROPiCS-02 trial of Trodelvy (sacituzumab govitecan-hziy) in previously treated metastatic hormone receptor (HR)-positive/HER2-negative breast cancer met the key secondary endpoint of overall survival (OS), but without detailed results it remains unclear whether that will help the drug’s competitive position on the market relative to other therapies that have also shown a survival advantage.

Without disclosing the data, the company said 15 August that the Phase III trial, in patients previously treated with endocrine therapy, CDK4/6 inhibitors and two to four lines of chemotherapy, had met the OS secondary endpoint